Journal of Clinical Endocrinology & Metabolism, Vol 79, 1693-1700, Copyright © 1994 by Endocrine Society

ARTICLES

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

P Garnero, WJ Shih, E Gineyts, DB Karpf and PD Delmas
INSERM U-403, Hopital E. Herriot, Lyon, France.

To evaluate the clinical utility of recently developed biochemical markers of bone turnover to monitor the response of osteoporotic patients to antiresorptive therapy, we compared the results of three advanced assays for markers of bone resorption and four of bone formation to high pressure liquid chromatography (HPLC)-fluorometric assays for urinary pyridinoline and deoxypyridinoline. These assays were also used to resolve the uncertainties concerning the rate of bone turnover in late postmenopausal (late-PMP) osteoporotic women. The rate of bone turnover in 85 women (mean +/- SD age, 63 +/- 6 yr) with low bone mass and all more than 5 yr postmenopausal (mean +/- SD yr PMP, 16 +/- 7 yr) was compared to that in 46 premenopausal women (mean +/- SD age, 40 +/- 5 yr) randomly selected from a large cohort and all having a normal spine bone mineral density (BMD). The late-PMP osteoporotic patients were a subset of patients enrolled in a double blind, placebo- controlled, randomized study comparing the effects of several doses of oral alendronate, a potent and specific inhibitor of bone resorption. Periodically during the 2-yr study, the women's spinal BMD and the level of several markers of bone turnover were measured. Serum total and intact osteocalcin, bone-specific alkaline phosphatase, and carboxy- terminal propeptide of type I collagen measured by RIA were used to assess bone formation. To assess bone resorption, we measured the urinary excretion of total pyridinoline (HPLC Pyr) and deoxypyridinoline (HPLC D-Pyr) by HPLC, type I collagen cross-linked N- telopeptide and urinary free PYR (F-Pyr) by enzyme-linked immunosorbent assay, and the serum concentration of type I collagen cross-linked C- telopeptide (ICTP) by RIA. All bone formation markers, except carboxy- terminal propeptide of type I collagen, and all bone resorption markers, except ICTP, were significantly increased above normal (33- 171%; P < 0.001) in late-PMP osteoporotic women. The long term within- patient variability assessed over a 15-month period in the placebo group was low and was somewhat lower for serum markers (12.5-17.4%) than for urinary markers (24-29%). Under treatment with alendronate, resorption markers decreased earlier than markers of bone formation, consistent with a direct action of the drug to inhibit osteoclastic bone resorption. With the exception of F-Pyr and ICTP, the levels of bone markers were reduced to the normal premenopausal range, and this steady state was maintained from 6-15 months.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				G. M. Blake, M. L. Frost, and I. Fogelman Quantitative Radionuclide Studies of Bone J. Nucl. Med., November 1, 2009; 50(11): 1747 - 1750. [Full Text] [PDF]

				A. E.B. Moore, G. M. Blake, and I. Fogelman Quantitative Measurements of Bone Remodeling Using 99mTc-Methylene Diphosphonate Bone Scans and Blood Sampling J. Nucl. Med., March 1, 2008; 49(3): 375 - 382. [Abstract] [Full Text] [PDF]

				M. E. Kraenzlin Biochemical Markers of Bone Turnover and Osteoporosis Management IBMS BoneKEy, July 1, 2007; 4(7): 191 - 203. [Abstract] [Full Text] [PDF]

				R. G. G. Russell Bisphosphonates: Mode of Action and Pharmacology Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162. [Abstract] [Full Text] [PDF]

				B. Weinstock-Guttman, J. Hong, R. Santos, M. Tamano-Blanco, D. Badgett, K. Patrick, M. Baier, J. Feichter, E. Gallagher, N. Garg, et al. Interferon-{beta} modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients Multiple Sclerosis, September 1, 2006; 12(5): 541 - 550. [Abstract] [PDF]

				A. J. Sanchez and J. Aranda-Michel Liver Disease and Osteoporosis Nutr Clin Pract, June 1, 2006; 21(3): 273 - 278. [Abstract] [Full Text] [PDF]

				D. T. Shaw, D. W. Rozeboom, G. M. Hill, M. W. Orth, D. S. Rosenstein, and J. E. Link Impact of supplement withdrawal and wheat middling inclusion on bone metabolism, bone strength, and the incidence of bone fractures occurring at slaughter in pigs J Anim Sci, May 1, 2006; 84(5): 1138 - 1146. [Abstract] [Full Text] [PDF]

				D. C. Bauer, P. Garnero, J. P. Bilezikian, S. L. Greenspan, K. E. Ensrud, C. J. Rosen, L. Palermo, D. M. Black, and for the PTH and Alendronate (PaTH) Research Group Short-Term Changes in Bone Turnover Markers and Bone Mineral Density Response to Parathyroid Hormone in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1370 - 1375. [Abstract] [Full Text] [PDF]

				K. K. Ivaska, K. Pettersson, A. Nenonen, K. Uusi-Rasi, A. Heinonen, P. Kannus, and H. K. Vaananen Urinary Osteocalcin Is a Useful Marker for Monitoring the Effect of Alendronate Therapy Clin. Chem., December 1, 2005; 51(12): 2362 - 2365. [Full Text] [PDF]

				M. R. McClung, J. San Martin, P. D. Miller, R. Civitelli, F. Bandeira, M. Omizo, D. W. Donley, G. P. Dalsky, and E. F. Eriksen Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass Arch Intern Med, August 8, 2005; 165(15): 1762 - 1768. [Abstract] [Full Text] [PDF]

				K. Kananen, L. Volin, K. Laitinen, H. Alfthan, T. Ruutu, and M. J. Valimaki Prevention of Bone Loss after Allogeneic Stem Cell Transplantation by Calcium, Vitamin D, and Sex Hormone Replacement with or without Pamidronate J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3877 - 3885. [Abstract] [Full Text] [PDF]

				H. Dobnig, A. Sipos, Y. Jiang, A. Fahrleitner-Pammer, L.-G. Ste-Marie, J. C. Gallagher, I. Pavo, J. Wang, and E. F. Eriksen Early Changes in Biochemical Markers of Bone Formation Correlate with Improvements in Bone Structure during Teriparatide Therapy J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3970 - 3977. [Abstract] [Full Text] [PDF]

				F Hanna, P R Ebeling, Y Wang, R O'Sullivan, S Davis, A E Wluka, and F M Cicuttini Factors influencing longitudinal change in knee cartilage volume measured from magnetic resonance imaging in healthy men Ann Rheum Dis, July 1, 2005; 64(7): 1038 - 1042. [Abstract] [Full Text] [PDF]

				C. V. Odvina, J. E. Zerwekh, D. S. Rao, N. Maalouf, F. A. Gottschalk, and C. Y. C. Pak Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1294 - 1301. [Abstract] [Full Text] [PDF]

				S. Epstein The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy Mayo Clin. Proc., March 1, 2005; 80(3): 379 - 388. [Abstract] [PDF]

				C. E. Bolton, A. A. Ionescu, K. M. Shiels, R. J. Pettit, P. H. Edwards, M. D. Stone, L. S. Nixon, W. D. Evans, T. L. Griffiths, and D. J. Shale Associated Loss of Fat-free Mass and Bone Mineral Density in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1286 - 1293. [Abstract] [Full Text] [PDF]

				M. Worsfold, D. E. Powell, T. J.W. Jones, and M. W.J. Davie Assessment of Urinary Bone Markers for Monitoring Treatment of Osteoporosis Clin. Chem., December 1, 2004; 50(12): 2263 - 2270. [Abstract] [Full Text] [PDF]

				M. R. McClung, R. D. Wasnich, D. J. Hosking, C. Christiansen, P. Ravn, M. Wu, A. M. Mantz, J. Yates, P. D. Ross, A. C. Santora II, et al. Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4879 - 4885. [Abstract] [Full Text] [PDF]

				E. Nikander, M. Metsa-Heikkila, O. Ylikorkala, and A. Tiitinen Effects of Phytoestrogens on Bone Turnover in Postmenopausal Women with a History of Breast Cancer J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1207 - 1212. [Abstract] [Full Text] [PDF]

				S. Evio, A. Tiitinen, K. Laitinen, O. Ylikorkala, and M. J. Valimaki Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 626 - 631. [Abstract] [Full Text] [PDF]

				Y. Yamori, E. H. Moriguchi, T. Teramoto, A. Miura, Y. Fukui, K.-i. Honda, M. Fukui, Y. Nara, K. Taira, and Y. Moriguchi Soybean Isoflavones Reduce Postmenopausal Bone Resorption in Female Japanese Immigrants in Brazil: A Ten-Week Study J. Am. Coll. Nutr., December 1, 2002; 21(6): 560 - 563. [Abstract] [Full Text] [PDF]

				K. V Haderslev, L. Tjellesen, H. A Sorensen, and M. Staun Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition Am. J. Clinical Nutrition, August 1, 2002; 76(2): 482 - 488. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, M. Sowers, G. A. Greendale, M.-L. T. Lee, R. M. Neer, J. A. Cauley, and B. Ettinger Ethnic Variation in Bone Turnover in Pre- and Early Perimenopausal Women: Effects of Anthropometric and Lifestyle Factors J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3051 - 3056. [Abstract] [Full Text] [PDF]

				T. Uesugi, Y. Fukui, and Y. Yamori Beneficial Effects of Soybean Isoflavone Supplementation on Bone Metabolism and Serum Lipids in Postmenopausal Japanese Women: A Four-Week Study J. Am. Coll. Nutr., April 1, 2002; 21(2): 97 - 102. [Abstract] [Full Text] [PDF]

				G. M. Blake, S.-J. Park-Holohan, and I. Fogelman Quantitative Studies of Bone in Postmenopausal Women Using 18F-Fluoride and 99mTc-Methylene Diphosphonate J. Nucl. Med., March 1, 2002; 43(3): 338 - 345. [Abstract] [Full Text] [PDF]

				I. R. Reid, J. P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J.-P. Devogelaer, J.-M. Kaufman, P. Jaeger, et al. Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density N. Engl. J. Med., February 28, 2002; 346(9): 653 - 661. [Abstract] [Full Text] [PDF]

				V. Parikka, P. Lehenkari, M.-L. Sassi, J. Halleen, J. Risteli, P. Harkonen, and H. K. Vaananen Estrogen Reduces the Depth of Resorption Pits by Disturbing the Organic Bone Matrix Degradation Activity of Mature Osteoclasts Endocrinology, December 1, 2001; 142(12): 5371 - 5378. [Abstract] [Full Text] [PDF]

				R. P. Tonino, A. Santora, and P. D. Ross Safety of Long-Term Alendronate J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1835a - 1836. [Full Text]

				D. Altkorn and T. Vokes Treatment of Postmenopausal Osteoporosis JAMA, March 21, 2001; 285(11): 1415 - 1418. [Full Text] [PDF]

				J. H. Tobias, S. Clarke, K. Mitchell, S. Robins, H. Amer, and W. D. Fraser Analysis of the Contribution of Dydrogesterone to Bone Turnover Changes in Postmenopausal Women Commencing Hormone Replacement Therapy J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1194 - 1198. [Abstract] [Full Text]

				G. G. Reinholz, B. Getz, L. Pederson, E. S. Sanders, M. Subramaniam, J. N. Ingle, and T. C. Spelsberg Bisphosphonates Directly Regulate Cell Proliferation, Differentiation, and Gene Expression in Human Osteoblasts Cancer Res., November 1, 2000; 60(21): 6001 - 6007. [Abstract] [Full Text]

				S. L. Greenspan, H. N. Rosen, and R. A. Parker Early Changes in Serum N-Telopeptide and C-Telopeptide Cross-Linked Collagen Type 1 Predict Long-Term Response to Alendronate Therapy in Elderly Women J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3537 - 3540. [Abstract] [Full Text]

				A. Scheja, M. Wildt, F. A. Wollheim, A. Akesson, and T. Saxne Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement Rheumatology, October 1, 2000; 39(10): 1110 - 1113. [Abstract] [Full Text] [PDF]

				C. R. Meier, R. G. Schlienger, M. E. Kraenzlin, B. Schlegel, and H. Jick HMG-CoA Reductase Inhibitors and the Risk of Fractures JAMA, June 28, 2000; 283(24): 3205 - 3210. [Abstract] [Full Text] [PDF]

				P. Ravn, M. Bidstrup, R. D. Wasnich, J. W. Davis, M. R. McClung, A. Balske, C. Coupland, O. Sahota, A. Kaur, M. Daley, et al. Alendronate and Estrogen-Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial Ann Intern Med, December 21, 1999; 131(12): 935 - 942. [Abstract] [Full Text] [PDF]

				T. Srivastava and U. S. Alon Bisphosphonates: From Grandparents to Grandchildren Clinical Pediatrics, November 1, 1999; 38(12): 687 - 702. [Abstract] [PDF]

				M. Sarno, H. Powell, G. Tjersland, D. Schoendorfer, H. Harris, K. Adams, P. Ogata, and G. R. Warnick A Collection Method and High-Sensitivity Enzyme Immunoassay for Sweat Pyridinoline and Deoxypyridinoline Cross-Links Clin. Chem., September 1, 1999; 45(9): 1501 - 1509. [Abstract] [Full Text] [PDF]

				A. Rubinacci, R. Melzi, M. Zampino, A. Soldarini, and I. Villa Total and Free Deoxypyridinoline after Acute Osteoclast Activity Inhibition Clin. Chem., September 1, 1999; 45(9): 1510 - 1516. [Abstract] [Full Text] [PDF]

				A. Berruti, L. Dogliotti, G. Gorzegno, M. Torta, M. Tampellini, M. Tucci, S. Cerutti, M. Mosca Frezet, M. Stivanello, G. Sacchetto, et al. Differential Patterns of Bone Turnover in Relation to Bone Pain and Disease Extent in Bone in Cancer Patients with Skeletal Metastases Clin. Chem., August 1, 1999; 45(8): 1240 - 1247. [Abstract] [Full Text] [PDF]

				N. B. Watts Clinical Utility of Biochemical Markers of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1359 - 1368. [Abstract] [Full Text] [PDF]

				P. Ravn, D. Hosking, D. Thompson, G. Cizza, R. D. Wasnich, M. McClung, A. J. Yates, N. H. Bjarnason, and C. Christiansen Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2363 - 2368. [Abstract] [Full Text]

				B. C. Kress, I. A. Mizrahi, K. W. Armour, R. Marcus, R. D. Emkey, and A. C. Santora II Use of Bone Alkaline Phosphatase to Monitor Alendronate Therapy in Individual Postmenopausal Osteoporotic Women Clin. Chem., July 1, 1999; 45(7): 1009 - 1017. [Abstract] [Full Text] [PDF]

				B. J. Orr-Walker, A. M. Horne, M. C. Evans, A. B. Grey, M. A. F. Murray, A. R. McNeil, and I. R. Reid Hormone Replacement Therapy Causes a Respiratory Alkalosis in Normal Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1997 - 2001. [Abstract] [Full Text]

				A. W. Al-Dehaimi, A. Blumsohn, and R. Eastell Serum Galactosyl Hydroxylysine as a Biochemical Marker of Bone Resorption Clin. Chem., May 1, 1999; 45(5): 676 - 681. [Abstract] [Full Text] [PDF]

				O M Crosbie, R Freaney, M J McKenna, M P Curry, and J E Hegarty Predicting bone loss following orthotopic liver transplantation Gut, March 1, 1999; 44(3): 430 - 434. [Abstract] [Full Text] [PDF]

				E. S. Orwoll, N. H. Bell, M. S. Nanes, K. A. Flessland, M. B. Pettinger, N. J. S. Mallinak, and D. F. Cain Collagen N-Telopeptide Excretion in Men: The Effects of Age and Intrasubject Variability J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3930 - 3935. [Abstract] [Full Text]

				S. Christgau, C. Rosenquist, P. Alexandersen, N. H. Bjarnason, P. Ravn, C. Fledelius, C. Herling, P. Qvist, and C. Christiansen Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides Clin. Chem., November 1, 1998; 44(11): 2290 - 2300. [Abstract] [Full Text] [PDF]

				S. M. Smith, J. L. Nillen, A. LeBlanc, A. Lipton, L. M. Demers, H. W. Lane, and C. S. Leach Collagen Cross-Link Excretion during Space Flight and Bed Rest J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3584 - 3591. [Abstract] [Full Text]

				T. G. Rosano, R. T. Peaston, H. G. Bone, H. W. Woitge, R. M. Francis, and M. J. Seibel Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation Clin. Chem., October 1, 1998; 44(10): 2126 - 2132. [Abstract] [Full Text] [PDF]

				D. L. Broyles, R. G. Nielsen, E. M. Bussett, W. D. Lu, I. A. Mizrahi, P. A. Nunnelly, T. A. Ngo, J. Noell, R. H. Christenson, and B. C. Kress Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase Clin. Chem., October 1, 1998; 44(10): 2139 - 2147. [Abstract] [Full Text] [PDF]

				E. E. Fradinger, G. Rodriguez, C. Bogado, and J. R. Zanchetta Effect of Antiresorptive Therapy on Day-to-Day Variation of Urinary Free Deoxypyridinoline Excretion Clin. Chem., October 1, 1998; 44(10): 2224 - 2225. [Full Text] [PDF]

				J. M. Blatt, M. P. Allen, S. Baddam, B. N. Dasu, D. M. Dickens, S. J. Hardt, R. T. Hebert, Y.-C. Hsu, C. T. Kitazawa, S.-F. Li, et al. A Miniaturized, Self-contained, Single-use, Disposable Assay Device for the Quantitative Determination of the Bone Resorption Marker, NTx, in Urine Clin. Chem., September 1, 1998; 44(9): 2051 - 2052. [Full Text] [PDF]

				H. N. Rosen, A. C. Moses, J. Garber, D. S. Ross, S. L. Lee, L. Ferguson, V. Chen, K. Lee, and S. L. Greenspan Randomized Trial of Pamidronate in Patients with Thyroid Cancer: Bone Density Is Not Reduced by Suppressive Doses of Thyroxine, But Is Increased by Cyclic Intravenous Pamidronate J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2324 - 2330. [Abstract] [Full Text]

				S. Kamel, P. Fardellone, B. Meddah, F. Lorget-Gondelmann, J. L. Sebert, and M. Brazier Response of several markers of bone collagen degradation to calcium supplementation in postmenopausal women with low calcium intake Clin. Chem., July 1, 1998; 44(7): 1437 - 1442. [Abstract] [Full Text] [PDF]

				M. B. Marttunen, P. Hietanen, A. Tiitinen, and O. Ylikorkala Comparison of Effects of Tamoxifen and Toremifene on Bone Biochemistry and Bone Mineral Density in Postmenopausal Breast Cancer Patients J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1158 - 1162. [Abstract] [Full Text]

				R. Eastell Treatment of Postmenopausal Osteoporosis N. Engl. J. Med., March 12, 1998; 338(11): 736 - 746. [Full Text] [PDF]

				H. Fleisch Bisphosphonates: Mechanisms of Action Endocr. Rev., February 1, 1998; 19(1): 80 - 100. [Abstract] [Full Text]

				E. A. Amama, M. Taga, and H. Minaguchi The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 333 - 338. [Abstract] [Full Text]

				J. D. Clemens, M. V. Herrick, F. R. Singer, and D. R. Eyre Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption Clin. Chem., November 1, 1997; 43(11): 2058 - 2063. [Abstract] [Full Text] [PDF]

				P. J. Meunier, E. Confavreux, I. Tupinon, C. Hardouin, P. D. Delmas, and R. Balena Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up) J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2784 - 2791. [Abstract] [Full Text] [PDF]

				M. J. De Souza, B. E. Miller, L. C. Sequenzia, A. A. Luciano, S. Ulreich, S. Stier, K. Prestwood, and B. L. Lasley Bone Health Is Not Affected by Luteal Phase Abnormalities and Decreased Ovarian Progesterone Production in Female Runners J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2867 - 2876. [Abstract] [Full Text] [PDF]

				P. Bettica, M. Bevilacqua, T. Vago, M. Masino, E. Cucinotta, and G. Norbiato Short-Term Variations in Bone Remodeling Biochemical Markers: Cyclical Etidronate and Alendronate Effects Compared J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3034 - 3039. [Abstract] [Full Text] [PDF]

				W. Withold, H. W. Woitge, and M. J. Seibel More on Total and Bone-Specific Alkaline Phosphatase • Authors of the article referred to respond: Clin. Chem., September 1, 1997; 43(9): 1670 - 1671. [Full Text]

				J. D. Adachi, W. G. Bensen, J. Brown, D. Hanley, A. Hodsman, R. Josse, D. L. Kendler, B. Lentle, W. Olszynski, L.-G. Ste.-Marie, et al. Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis N. Engl. J. Med., August 7, 1997; 337(6): 382 - 388. [Abstract] [Full Text] [PDF]

				D. L. Schneider and E. L. Barrett-Connor Urinary N-Telopeptide Levels Discriminate Normal, Osteopenic, and Osteoporotic Bone Mineral Density Arch Intern Med, June 9, 1997; 157(11): 1241 - 1245. [Abstract] [PDF]

				C. J. Rosen, C. H. Chesnut III, and N. J. S. Mallinak The Predictive Value of Biochemical Markers of Bone Turnover for Bone Mineral Density in Early Postmenopausal Women Treated with Hormone Replacement or Calcium Supplementation J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1904 - 1910. [Abstract] [Full Text] [PDF]

				D. B. Karpf, D. R. Shapiro, E. Seeman, K. E. Ensrud, C. C. Johnston Jr, S. Adami, S. T. Harris, A. C. Santora II, L. J. Hirsch, L. Oppenheimer, et al. Prevention of Nonvertebral Fractures by Alendronate: A Meta-analysis JAMA, April 9, 1997; 277(14): 1159 - 1164. [Abstract] [PDF]

				A. B. Hodsman, L. J. Fraher, P. H. Watson, T. Ostbye, L. W. Stitt, J. D. Adachi, D. H. Taves, and D. Drost A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 620 - 628. [Abstract] [Full Text] [PDF]

				P. D. Ross Osteoporosis: Frequency, Consequences, and Risk Factors Arch Intern Med, July 8, 1996; 156(13): 1399 - 1411. [Abstract] [PDF]

				U. A. Liberman, S. R. Weiss, J. Broll, H. W. Minne, H. Quan, N. H. Bell, J. Rodriguez-Portales, R. W. Downs, J. Dequeker, M. Favus, et al. Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis N. Engl. J. Med., November 30, 1995; 333(22): 1437 - 1444. [Abstract] [Full Text] [PDF]